Institutional Ownership
4d Molecular Therapeutics In
CUSIP 35104E100COMFDMTQ1 2026
13D / 13G Filings
62
Schedule 13D/13G on record
Beneficial Filers
18
Distinct reporting persons
Largest Stake
14.9%
Max % of class reported
Institutional Holders
149
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
62 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Novo Holdings A/S | 13G/A | 6.4% | 3.65M | SEC |
| 2 | Feb 17, 2026 | Ra Capital Management, L.P. | 13G/A | 9.9% | 5.71M | SEC |
| 3 | Feb 17, 2026 | Janus Henderson Group PLC | 13G | 8.1% | 4.64M | SEC |
| 4 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 10.0% | 5.85M | SEC |
| 5 | Feb 9, 2026 | The Goldman Sachs Group, Inc. | 13G/A | 11.0% | 4.29M | SEC |
| 6 | Oct 20, 2025 | Novo Holdings A/S | 13G | 6.8% | 3.17M | SEC |
| 7 | Oct 17, 2025 | Blackrock, Inc. | 13G/A | 6.6% | 3.06M | SEC |
| 8 | May 15, 2025 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 1.5% | 677.6K | SEC |
| 9 | May 15, 2025 | Biotechnology Value Fund L P | 13G/A | 10.0% | 4.63M | SEC |
| 10 | Apr 17, 2025 | Blackrock, Inc. | 13G/A | 7.8% | 3.62M | SEC |
52 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for 4d Molecular Therapeutics In.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Janus Henderson Group PLC | 5.25M | $48.87M |
| 2 | Ra Capital Management, L.P. | 5.05M | $47.01M |
| 3 | Goldman Sachs Group Inc | 4.21M | $39.15M |
| 4 | Blackrock, Inc. | 4.15M | $38.59M |
| 5 | Novo Holdings A/S | 3.65M | $33.99M |
| 6 | Bvf Inc/Il | 2.88M | $26.81M |
| 7 | State Street Corp | 2.71M | $25.21M |
| 8 | Vanguard Capital Management LLC | 2.20M | $20.44M |
| 9 | Armistice Capital, LLC | 2.00M | $18.62M |
| 10 | Adage Capital Partners Gp, L.L.C. | 1.61M | $14.94M |